Tenax Therapeutics's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.35.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.40.
During the past 3 years, the average EPS without NRIGrowth Rate was 86.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 82.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 63.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Tenax Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 92.30% per year. The lowest was -68.30% per year. And the median was 26.50% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Tenax Therapeutics EPS (Diluted) Related Terms
Tenax Therapeutics EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for Tenax Therapeutics's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TENX vs RCKT, AVIR, VNDA: EPS (Diluted) Comparison
For the Biotechnology subindustry, Tenax Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Tenax Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (TENX) has a EPS (Diluted) of $-1.40 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Tenax Therapeutics and its competitors.
Is Tenax Therapeutics' EPS (Diluted) too high?
Tenax Therapeutics' current EPS (Diluted) is $-1.40. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' EPS (Diluted) compare to RCKT and AVIR?
Tenax Therapeutics' EPS (Diluted) of $-1.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Tenax Therapeutics and its competitors. Tenax Therapeutics's current EPS (Diluted) is $-1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current EPS (Diluted) of $-1.40. The current EPS (Diluted) is $-1.40. Tenax Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current EPS (Diluted) is $-1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score
Get the complete analysis for TENX
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TENX has been successfully added to your 
